Pharma Focus America

Astellas Receives SBTi Approval for Revised Science-Based Climate Goals to Reduce Greenhouse Gas Emissions

Friday, January 20, 2023

Astellas Pharma Inc., announced that the Science Based Targets initiative (SBTi)*1 has validated and approved its greenhouse gas (GHG) emissions reduction targets. The targets, as a science-based initiative, have been approved towards achieving the 1.5 degrees Celsius and well-below 2 degrees Celsius targets of the Paris Climate Agreement.

Astellas has set "Deepen our engagement in sustainability" as one of the strategic goals in its Corporate Strategic Plan 2021. The reduction of environmental burden is Astellas' priority themes within sustainability.

"For society and Astellas to continue to grow sustainably, we recognize that we need to be conscious of the issues affecting our planet and climate change," said Kenji Yasukawa, President and CEO, Astellas. "Climate change is one of our key issues to address. SBTi certification represents significant progress on environmental sustainability for us under our Corporate Strategic Plan 2021, and we are determined to achieve these goals."

Astellas' revised targets are as follows:

  • Astellas commits to reduce absolute scope 1 and 2*2 GHG emissions by 63% by FY2030 from the FY2015 base year. <1.5 degrees Celsius target>
  • Astellas also commits to reduce absolute scope 3*2 GHG emissions by 37.5% by FY2030 from the FY2015 base year.

For more information on specific initiatives, please visit our website.

Astellas continues to further promote sustainability activities and expand information disclosure under its basic policy, which is to improve the sustainability of both the global society and Astellas while keeping ESG [environmental (E), social (S), governance (G)] in mind.

Thermo Fisher Scientific - mRNA ServicesFuture Labs Live USA 2024World Vaccine Congress Europe 2024World Orphan Drug Congress 2024Advanced Therapies USA 2024World Orphan Drug Congress Europe 2024